RIO DE JANEIRO, BRAZIL – Brazil’s National Health Regulator (Anvisa) on Monday (19) authorized a study to measure the safety and efficacy of a third dose of AstraZeneca’s Covid-19 vaccine, the regulatory agency said in a statement.
According to Anvisa, the study, sponsored by AstraZeneca, will be conducted with the participants of the initial research study who received the two doses of the vaccine four weeks apart. The third dose will be applied between 11 and 13 months after the second dose.
The study will be conducted only in Brazil with 10,000 volunteers in Bahia, Rio de Janeiro, Rio Grande do Sul, Rio Grande do Norte, and São Paulo, according to a statement by Anvisa.
The agency also advised that it authorized a clinical study to evaluate the safety and efficacy of the drug Proxalutamide in reducing the viral infection caused by the new coronavirus and the inflammatory process caused by Covid-19.
This study will be done in male outpatient participants with mild to moderate Covid-19 and is sponsored by Chinese Suzhou Kintor Pharmaceuticals.
The research will be conducted in Germany, Argentina, South Africa, Ukraine, Mexico, the United States, and Brazil, where 12 volunteers will participate in the State of Roraima and another 38 in São Paulo.